Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022)
Ginkgo Bioworks Holdings (DNA) posted Income from Non-Controlling Interests of $2.4 million for Q4 2022, up 236.96% on a QoQ basis from -$1.7 million in Q2 2022, and up 155.08% year-over-year from $936954.3 in Q4 2021.
Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Ginkgo Bioworks Holdings' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $2.4 million for Q4 2022.
- Quarterly Income from Non-Controlling Interests rose 155.08% year-over-year to $2.4 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was $2.4 million (up 129.25% YoY) and the FY2022 annual result came in at -$1.4 million, up 78.12% from the prior year.
- Income from Non-Controlling Interests was $2.4 million for Q4 2022 at Ginkgo Bioworks Holdings, up from -$1.7 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.4 million in Q4 2022 and bottomed at -$4.3 million in Q4 2021.
- A 3-year average of -$968888.9 and a median of -$753000.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests slumped 838.03% — and 2022, when it surged 155.08%.
- Ginkgo Bioworks Holdings' Income from Non-Controlling Interests stood at -$753000.0 in 2020, then sank by 476.23% to -$4.3 million in 2021, then jumped by 155.08% to $2.4 million in 2022.
- Business Quant data shows DNA's Income from Non-Controlling Interests at $2.4 million in Q4 2022, -$1.7 million in Q2 2022, and -$2.1 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 441.96 Mn | 298.10 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.39 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -524,000.00 |
| Jun 30, 2021 | -523,000.00 |
| Mar 31, 2021 | -1.21 Mn |
| Dec 31, 2020 | -753,000.00 |
| Sep 30, 2020 | 71,000.00 |